Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (NCT06191744)

🧪 Interventions in This Study

• Epcoritamab (DRUG)
• Prednisone (DRUG)
• Rituximab (DRUG)
• Lenalidomide (DRUG)
• Doxorubicin (DRUG)
• Vincristine (DRUG)
• Cyclophosphamide (DRUG)
• Obinutuzumab (DRUG)
• Bendamustine (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Diagnosis of follicular lymphoma (FL).
2. Have CD20+, histologically confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor biopsy based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours.
3. Are willing and able to comply with procedures required in the protocol.
4. Must have stage, III, IV or II with bulky disease \>= 7cm).
5. Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.
6. Has one or more target lesions:
7. A positron emission tomography (PET)/computerized tomography (CT) scan demonstrating PET-positive lesion(s), and
8. \>=1 measurable nodal lesion (long axis \>1.5cm) or \>=1 measurable extra-nodal lesion (long axis \>1.0 cm) on CT scan or MRI
9. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
10. Able to receive at least one of the standard of care chemoimmunotherapy (CIT) treatment regimens: \[Arm B\] at the discretion of the Investigator, and rituximab and lenalidomide (R2) \[Arm C\].
11. Have laboratory values meeting the criteria in the protocol.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (266 Sites)

Showing the first 25 of 266 sites.

• UCSF Fresno /ID# 264712 — Fresno, California
• Scripps Mercy Hospital /ID# 265393 — San Diego, California
• Sansum Clinic Research /ID# 261596 — Santa Barbara, California
• Rocky Mountain Cancer Centers - Boulder /ID# 261203 — Boulder, Colorado
• Christiana Care Health Service /ID# 261207 — Newark, Delaware
• Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 262445 — Jacksonville, Florida
• Advent Health /ID# 261578 — Orlando, Florida
• Orlando Health Cancer Institute /ID# 260983 — Orlando, Florida
• Moffitt Cancer Center /ID# 259487 — Tampa, Florida
• Beacon Cancer Care - Coeur d'Alene /ID# 260670 — Coeur d'Alene, Idaho
• Northwestern Medicine - Northwestern Memorial Hospital /ID# 259814 — Chicago, Illinois
• Cancer Care Specialists Of Central Illinois /ID# 272464 — Decatur, Illinois
• Loyola University /ID# 259462 — Maywood, Illinois
• Illinois Cancer Care, PC /ID# 261526 — Peoria, Illinois
• Fort Wayne Medical Oncology and Hematology- South Office /ID# 259583 — Fort Wayne, Indiana
• University of Iowa Health Care /ID# 262132 — Des Moines, Iowa
• University of Louisville Hospital /ID# 260544 — Louisville, Kentucky
• Norton Cancer Institute - St. Matthews /ID# 261076 — Louisville, Kentucky
• New England Cancer Specialists - Westbrook /ID# 260672 — Westbrook, Maine
• University of Maryland, Baltimore /ID# 259538 — Baltimore, Maryland
• Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 259476 — Bethesda, Maryland
• St. Luke's Hospital - Chesterfield /ID# 260489 — Chesterfield, Missouri
• Intermountain Health St Vincent Regional Hospital - Cancer Centers of Montana /ID# 260006 — Billings, Montana
• Nebraska Cancer Specialists (NCS) - Regional Cancer Center - St Francis Location /ID# 262506 — Grand Island, Nebraska
• Nebraska Hematology-Oncology /ID# 269692 — Lincoln, Nebraska

📞 Contact the Study Coordinator

Phone: (877) 827-3222

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
• 💵 Compensation indicated: Participants will receive R2 (intravenous \[IV\] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab.

More studies in Follicular Lymphoma (FL)

• A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma — Camperdown, New South Wales
• A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma — Tucson, Arizona
• A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma — Plantation, Florida
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma — Tucson, Arizona

Explore by condition: All Follicular Lymphoma (FL) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.